Literature DB >> 28820726

Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series.

Alexander J Millman1, Boatemaa Ntiri-Reid2, Risha Irvin3, Maggie H Kaufmann4, Andrew Aronsohn5, Jeffrey S Duchin6, John D Scott7, Claudia Vellozzi1.   

Abstract

Restrictive policies on access to new, curative hepatitis C treatments represent a substantial barrier to treating patients infected with hepatitis C. This case series demonstrates challenges experienced by patients and practitioners in accessing these treatments and highlights several strategies for navigating the treatment preauthorization process.

Entities:  

Mesh：

Year:  2017        PMID： 28820726      PMCID： PMC5678961     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN： 2161-5853


  13 in total

1.  Early Patterns of Sofosbuvir Utilization by State Medicaid Programs.

Authors:  Joshua M Liao; Michael A Fischer
Journal:  N Engl J Med       Date:  2015-09-24       Impact factor: 91.245

2.  Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs.

Authors:  John W Ward; Jonathan H Mermin
Journal:  N Engl J Med       Date:  2015-11-17       Impact factor: 91.245

3.  Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.

Authors:  Lauren A Canary; R Monina Klevens; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2015-08-04       Impact factor: 25.391

4.  Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program.

Authors:  Stacey B Trooskin; Joanna Poceta; Caitlin M Towey; Annajane Yolken; Jennifer S Rose; Najia L Luqman; Ta-Wanda L Preston; Philip A Chan; Curt Beckwith; Sophie C Feller; Hwajin Lee; Amy S Nunn
Journal:  J Gen Intern Med       Date:  2015-02-14       Impact factor: 5.128

Review 5.  Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.

Authors:  Jaimie P Meyer; Yavar Moghimi; Ruthanne Marcus; Joseph K Lim; Alain H Litwin; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2015-05-17

6.  The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.

Authors:  David B Rein; John S Wittenborn; Bryce D Smith; Danielle K Liffmann; John W Ward
Journal:  Clin Infect Dis       Date:  2015-03-16       Impact factor: 9.079

7.  Primary Care Physician Perspectives on Hepatitis C Management in the Era of Direct-Acting Antiviral Therapy.

Authors:  Mary Thomson; Monica A Konerman; Hetal Choxi; Anna S F Lok
Journal:  Dig Dis Sci       Date:  2016-03-08       Impact factor: 3.199

Review 8.  Access to treatment for hepatitis C virus infection: time to put patients first.

Authors:  Brian R Edlin
Journal:  Lancet Infect Dis       Date:  2016-07-13       Impact factor: 25.071

9.  Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.

Authors:  Z M Younossi; B R Bacon; D T Dieterich; S L Flamm; K Kowdley; S Milligan; N Tsai; A Nezam
Journal:  J Viral Hepat       Date:  2016-02-03       Impact factor: 3.728

10.  Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade.

Authors:  Albert Do; Yash Mittal; AnnMarie Liapakis; Elizabeth Cohen; Hong Chau; Claudia Bertuccio; Dana Sapir; Jessica Wright; Carol Eggers; Kristine Drozd; Maria Ciarleglio; Yanhong Deng; Joseph K Lim
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240
View more
  16 in total

Review 1.  Promising practices for the prevention of liver cancer: a review of the literature and cancer plan activities in the National Comprehensive Cancer Control Program.

Authors:  Behnoosh Momin; Alexander J Millman; Danielle Beauchesne Nielsen; Michelle Revels; C Brooke Steele
Journal:  Cancer Causes Control       Date:  2018-12-01       Impact factor: 2.506

2.  Elimination of Hepatitis B and C Virus Infections.

Authors:  Andrew Aronsohn
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-04

3.  Universal HCV Screening of Baby Boomers is Feasible, but It is Difficult.

Authors:  Paul J Thuluvath; Joshua Trowell; Talan Zhang; Joseph Alukal; George Lowe
Journal:  J Clin Exp Hepatol       Date:  2021-02-25

4.  Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.

Authors:  Marina Serper; Donna M Evon; Paul W Stewart; Anna S Lok; Jipcy Amador; Bryce B Reeve; Carol E Golin; Michael W Fried; K Rajender Reddy; Richard K Sterling; Souvik Sarkar; Adrian M Di Bisceglie; Joseph K Lim; David R Nelson; Nancy Reau
Journal:  J Gen Intern Med       Date:  2019-10-28       Impact factor: 5.128

5.  Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era.

Authors:  Autumn Zuckerman; Andrew Douglas; Sam Nwosu; Leena Choi; Cody Chastain
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

6.  Outcomes of a Pharmacist-Led Hepatitis C Virus Treatment Program in an Urban Safety-Net Health System, Chicago, 2017-2019.

Authors:  Bijou R Hunt; Hollyn Cetrone; Sharon Sam; Nancy R Glick
Journal:  Public Health Rep       Date:  2021-05-27       Impact factor: 3.117

7.  Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland.

Authors:  Risha Irvin; Boatemaa Ntiri-Reid; Mary Kleinman; Tracy Agee; Jeffrey Hitt; Onyeka Anaedozie; Tolu Arowolo; Hope Cassidy-Stewart; CaSaundra Bush; Lucy E Wilson; Alexander J Millman; Noele P Nelson; Lauren Canary; Sherilyn Brinkley; Juhi Moon; Oluwaseun Falade-Nwulia; Mark S Sulkowski; David L Thomas; Michael T Melia
Journal:  J Viral Hepat       Date:  2020-08-05       Impact factor: 3.517

8.  Project HELP: a study protocol to pilot test a shared decision-making tool about treatment options for patients with hepatitis C and chronic kidney disease.

Authors:  T Li; K M Korenblat; K J Fowler; C Ho; A Liapakis; D Roth; J Yee; M C Politi; N George
Journal:  Pilot Feasibility Stud       Date:  2018-02-21

9.  A Patient Decision Support Tool for Hepatitis C Virus and CKD Treatment.

Authors:  Nerissa George; AnnMarie Liapakis; Kevin M Korenblat; Tingting Li; David Roth; Jerry Yee; Kevin J Fowler; Lehman Howard; Jingxia Liu; Mary C Politi
Journal:  Kidney Med       Date:  2019-07-11

Review 10.  The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review.

Authors:  John T Kanazawa; Parya Saberi; John A Sauceda; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2020-12-07       Impact factor: 2.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.